Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

Publikation: Bidrag til tidsskriftReviewForskningpeer review

Harvard

Younes, A, Hilden, P, Coiffier, B, Hagenbeek, A, Salles, G, Wilson, W, Seymour, JF, Kelly, K, Gribben, J, Pfreunschuh, M, Morschhauser, F, Schoder, H, Zelenetz, AD, Rademaker, J, Advani, R, Valente, N, Fortpied, C, Witzig, TE, Sehn, LH, Engert, A, Fisher, RI, Zinzani, P-L, Federico, M, Hutchings, M, Bollard, C, Trneny, M, Elsayed, YA, Tobinai, K, Abramson, JS, Fowler, N, Goy, A, Smith, M, Ansell, S, Kuruvilla, J, Dreyling, M, Thieblemont, C, Little, RF, Aurer, I, Van Oers, MHJ, Takeshita, K, Gopal, A, Rule, S, de Vos, S, Kloos, I, Kaminski, MS, Meignan, M, Schwartz, LH, Leonard, JP, Schuster, SJ & Seshan, VE 2017, 'International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)' Annals of Oncology, bind 28, nr. 7, s. 1436-1447. https://doi.org/10.1093/annonc/mdx097

APA

Younes, A., Hilden, P., Coiffier, B., Hagenbeek, A., Salles, G., Wilson, W., ... Seshan, V. E. (2017). International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Annals of Oncology, 28(7), 1436-1447. https://doi.org/10.1093/annonc/mdx097

CBE

Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani P-L, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MHJ, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE. 2017. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Annals of Oncology. 28(7):1436-1447. https://doi.org/10.1093/annonc/mdx097

MLA

Vancouver

Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W o.a. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Annals of Oncology. 2017 jul 1;28(7):1436-1447. https://doi.org/10.1093/annonc/mdx097

Author

Younes, A ; Hilden, P ; Coiffier, B ; Hagenbeek, A ; Salles, G ; Wilson, W ; Seymour, J F ; Kelly, K ; Gribben, J ; Pfreunschuh, M ; Morschhauser, F ; Schoder, H ; Zelenetz, A D ; Rademaker, J ; Advani, R ; Valente, N ; Fortpied, C ; Witzig, T E ; Sehn, L H ; Engert, A ; Fisher, R I ; Zinzani, P-L ; Federico, M ; Hutchings, M ; Bollard, C ; Trneny, M ; Elsayed, Y A ; Tobinai, K ; Abramson, J S ; Fowler, N ; Goy, A ; Smith, M ; Ansell, S ; Kuruvilla, J ; Dreyling, M ; Thieblemont, C ; Little, R F ; Aurer, I ; Van Oers, M H J ; Takeshita, K ; Gopal, A ; Rule, S ; de Vos, S ; Kloos, I ; Kaminski, M S ; Meignan, M ; Schwartz, L H ; Leonard, J P ; Schuster, S J ; Seshan, V E. / International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). I: Annals of Oncology. 2017 ; Bind 28, Nr. 7. s. 1436-1447.

Bibtex

@article{1965d6580ad84160995d0b17e33134b4,
title = "International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)",
abstract = "In recent years, the number of approved and investigational agents that can be safely administered for the treatment of lymphoma patients for a prolonged period of time has substantially increased. Many of these novel agents are evaluated in early-phase clinical trials in patients with a wide range of malignancies, including solid tumors and lymphoma. Furthermore, with the advances in genome sequencing, new {"}basket{"} clinical trial designs have emerged that select patients based on the presence of specific genetic alterations across different types of solid tumors and lymphoma. The standard response criteria currently in use for lymphoma are the Lugano Criteria which are based on [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography or bidimensional tumor measurements on computerized tomography scans. These differ from the RECIST criteria used in solid tumors, which use unidimensional measurements. The RECIL group hypothesized that single-dimension measurement could be used to assess response to therapy in lymphoma patients, producing results similar to the standard criteria. We tested this hypothesis by analyzing 47 828 imaging measurements from 2983 individual adult and pediatric lymphoma patients enrolled on 10 multicenter clinical trials and developed new lymphoma response criteria (RECIL 2017). We demonstrate that assessment of tumor burden in lymphoma clinical trials can use the sum of longest diameters of a maximum of three target lesions. Furthermore, we introduced a new provisional category of a minor response. We also clarified response assessment in patients receiving novel immune therapy and targeted agents that generate unique imaging situations.",
keywords = "Antineoplastic Agents, Consensus, Contrast Media, Disease Progression, Disease-Free Survival, Endpoint Determination, Fluorodeoxyglucose F18, Humans, Lymphoma, Non-Hodgkin, Neoplasm Staging, Positron-Emission Tomography, Predictive Value of Tests, Response Evaluation Criteria in Solid Tumors, Time Factors, Tomography, X-Ray Computed, Treatment Outcome, Tumor Burden, Consensus Development Conference, Journal Article, Practice Guideline, Review",
author = "A Younes and P Hilden and B Coiffier and A Hagenbeek and G Salles and W Wilson and Seymour, {J F} and K Kelly and J Gribben and M Pfreunschuh and F Morschhauser and H Schoder and Zelenetz, {A D} and J Rademaker and R Advani and N Valente and C Fortpied and Witzig, {T E} and Sehn, {L H} and A Engert and Fisher, {R I} and P-L Zinzani and M Federico and M Hutchings and C Bollard and M Trneny and Elsayed, {Y A} and K Tobinai and Abramson, {J S} and N Fowler and A Goy and M Smith and S Ansell and J Kuruvilla and M Dreyling and C Thieblemont and Little, {R F} and I Aurer and {Van Oers}, {M H J} and K Takeshita and A Gopal and S Rule and {de Vos}, S and I Kloos and Kaminski, {M S} and M Meignan and Schwartz, {L H} and Leonard, {J P} and Schuster, {S J} and Seshan, {V E}",
note = "{\circledC} The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology.",
year = "2017",
month = "7",
day = "1",
doi = "10.1093/annonc/mdx097",
language = "English",
volume = "28",
pages = "1436--1447",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "7",

}

RIS

TY - JOUR

T1 - International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

AU - Younes, A

AU - Hilden, P

AU - Coiffier, B

AU - Hagenbeek, A

AU - Salles, G

AU - Wilson, W

AU - Seymour, J F

AU - Kelly, K

AU - Gribben, J

AU - Pfreunschuh, M

AU - Morschhauser, F

AU - Schoder, H

AU - Zelenetz, A D

AU - Rademaker, J

AU - Advani, R

AU - Valente, N

AU - Fortpied, C

AU - Witzig, T E

AU - Sehn, L H

AU - Engert, A

AU - Fisher, R I

AU - Zinzani, P-L

AU - Federico, M

AU - Hutchings, M

AU - Bollard, C

AU - Trneny, M

AU - Elsayed, Y A

AU - Tobinai, K

AU - Abramson, J S

AU - Fowler, N

AU - Goy, A

AU - Smith, M

AU - Ansell, S

AU - Kuruvilla, J

AU - Dreyling, M

AU - Thieblemont, C

AU - Little, R F

AU - Aurer, I

AU - Van Oers, M H J

AU - Takeshita, K

AU - Gopal, A

AU - Rule, S

AU - de Vos, S

AU - Kloos, I

AU - Kaminski, M S

AU - Meignan, M

AU - Schwartz, L H

AU - Leonard, J P

AU - Schuster, S J

AU - Seshan, V E

N1 - © The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - In recent years, the number of approved and investigational agents that can be safely administered for the treatment of lymphoma patients for a prolonged period of time has substantially increased. Many of these novel agents are evaluated in early-phase clinical trials in patients with a wide range of malignancies, including solid tumors and lymphoma. Furthermore, with the advances in genome sequencing, new "basket" clinical trial designs have emerged that select patients based on the presence of specific genetic alterations across different types of solid tumors and lymphoma. The standard response criteria currently in use for lymphoma are the Lugano Criteria which are based on [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography or bidimensional tumor measurements on computerized tomography scans. These differ from the RECIST criteria used in solid tumors, which use unidimensional measurements. The RECIL group hypothesized that single-dimension measurement could be used to assess response to therapy in lymphoma patients, producing results similar to the standard criteria. We tested this hypothesis by analyzing 47 828 imaging measurements from 2983 individual adult and pediatric lymphoma patients enrolled on 10 multicenter clinical trials and developed new lymphoma response criteria (RECIL 2017). We demonstrate that assessment of tumor burden in lymphoma clinical trials can use the sum of longest diameters of a maximum of three target lesions. Furthermore, we introduced a new provisional category of a minor response. We also clarified response assessment in patients receiving novel immune therapy and targeted agents that generate unique imaging situations.

AB - In recent years, the number of approved and investigational agents that can be safely administered for the treatment of lymphoma patients for a prolonged period of time has substantially increased. Many of these novel agents are evaluated in early-phase clinical trials in patients with a wide range of malignancies, including solid tumors and lymphoma. Furthermore, with the advances in genome sequencing, new "basket" clinical trial designs have emerged that select patients based on the presence of specific genetic alterations across different types of solid tumors and lymphoma. The standard response criteria currently in use for lymphoma are the Lugano Criteria which are based on [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography or bidimensional tumor measurements on computerized tomography scans. These differ from the RECIST criteria used in solid tumors, which use unidimensional measurements. The RECIL group hypothesized that single-dimension measurement could be used to assess response to therapy in lymphoma patients, producing results similar to the standard criteria. We tested this hypothesis by analyzing 47 828 imaging measurements from 2983 individual adult and pediatric lymphoma patients enrolled on 10 multicenter clinical trials and developed new lymphoma response criteria (RECIL 2017). We demonstrate that assessment of tumor burden in lymphoma clinical trials can use the sum of longest diameters of a maximum of three target lesions. Furthermore, we introduced a new provisional category of a minor response. We also clarified response assessment in patients receiving novel immune therapy and targeted agents that generate unique imaging situations.

KW - Antineoplastic Agents

KW - Consensus

KW - Contrast Media

KW - Disease Progression

KW - Disease-Free Survival

KW - Endpoint Determination

KW - Fluorodeoxyglucose F18

KW - Humans

KW - Lymphoma, Non-Hodgkin

KW - Neoplasm Staging

KW - Positron-Emission Tomography

KW - Predictive Value of Tests

KW - Response Evaluation Criteria in Solid Tumors

KW - Time Factors

KW - Tomography, X-Ray Computed

KW - Treatment Outcome

KW - Tumor Burden

KW - Consensus Development Conference

KW - Journal Article

KW - Practice Guideline

KW - Review

U2 - 10.1093/annonc/mdx097

DO - 10.1093/annonc/mdx097

M3 - Review

VL - 28

SP - 1436

EP - 1447

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 7

ER -

ID: 52764973